Neurobiological underpinnings and modulating factors in schizophrenia spectrum disorders with a comorbid substance use disorder: A systematic review

Neuroscience and Biobehavioral Reviews

Volumn 75, Issue , 2017, Pages 361-377

  Adan, Ana ^a   Arredondo, Arantxa Y ^a   Capella, Maria del Mar ^a   Prat, Gemma ^a   Forero, Diego A ^b   Navarro, José Francisco ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIONES   (Colombia)

^c UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Comorbidity; Dual schizophrenia spectrum disorders; Illness duration; Neuroimaging; Schizophrenia; Schizophrenia spectrum disorders; Substance use disorders

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

AMPHETAMINE DEPENDENCE; AUTISM; BRAIN DYSFUNCTION; BRAIN FUNCTION; BRAIN SIZE; CANNABIS ADDICTION; COCAINE DEPENDENCE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DEPENDENCE; EMOTIONAL DISORDER; HUMAN; NEUROANATOMY; NEUROBIOLOGY; NEUROIMAGING; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT DURATION; PSYCHIATRIC DIAGNOSIS;

COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 85013059685     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2017.01.038     Document Type: Review

References (61)

1. American Psychiatric and Association, Diagnostic and Statistical Manual of Mental Disorders. 2013, American Psychiatric Publishing, Arlington, VA.
2. Arnold, C., Allott, K., Farhall, J., Killackey, E., Cotton, S., Neurocognitive and social cognitive predictors of cannabis use first-episode psychosis. Schizophr. Res. 168 (2015), 231–237.
3. Bangalore, S.S., Prasad, K.M.R., Montrose, D.M., Goradia, D.D., Diwadkar, V.A., Keshavan, M.S., Cannabis use and brain structural alterations in first episode schizophrenia- A region of interest, voxel based morphometric study. Schizophr. Res. 99 (2008), 1–6 (*).
4. Barrowclough, C., Eisnet, E., Bucci, S., Emsley, R., The impact of alcohol on clinical outcomes in established psychosis: a longitudinal study. Addiction 109:8 (2014), 1297–1305.
5. Benaiges, I., Serra-Grabulosa, J.M., Adan, A., Neuropsychological functioning and age-related changes in schizophrenia and/or cocaine dependence. Prog. Neuropsychopharmacol. Biol. Psychiatry 40 (2013), 298–305.
6. Benaiges, I., Serra-Grabulosa, J.M., Pratt, G., Adan, A., Executive functioning in individuals with schizophrenia and/or cocaine dependence. Hum. Psychopharmacol. 28:1 (2013), 29–39.
7. Bennett, M.E., Bellack, A.S., Brown, C.H., DiClemente, C., Substance dependence and remission in schizophrenia: a comparison of schizophrenia and affective disorders. Addict. Behav. 34 (2009), 806–814.
8. Boonstra, G., Cahn, W., Schnack, H.G., Hulshoff, H.E., Minderhoud, T.C., Kahn, R.S., van Haren, N.E.M., Duration of untreated illnes in schizophrenia is not associated with 5-year brain volume change. Schizophr. Res. 132 (2011), 84–90.
9. Bourque, J., Mendrek, A., Durand, M., Lakis, N., Lipp, O., Stip, E., Lalonde, P., Grignon, S., Potvin, S., Cannabis use is associated with better emotional memory in schizophrenia: a functional magnetic resonance imaging study. Psychiatry Res., 214(24–32), 2013 (*).
10. Buchy, L., Mathalon, D.H., Cannon, T.D., Cadenhead, K.S., Cornblatt, B.A., McGlashan, T.H., Perkins, D.O., Seidman, L., Tsuang, M.T., Walker, E.F., Woods, S.W., Bearden, C.E., Addington, J., Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. Psychiatry Res. 254 (2016), 3–9.
11. Buckley, P.F., Miller, B.J., Lerher, D.S., Castle, D.J., Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 35:2 (2009), 383–402.
12. Bugra, H., Studerus, E., Rapp, C., Tamagni, C., Aston, J., Borgwardt, S., Riecher-Rossler, A., Cannabis use and cognitive functions in at-risk mental state and first episode psychosis. Psychopharmacology (Berl.) 230 (2013), 299–308.
13. Cahn, W., Hulshoff Pol, H.E., Caspers, E., van Haren, N.E.M., Schnack, H.G., Kahn, R.S., Cannabis and brain morphology in recent-onset schizophrenia. Schizophr. Res. 67 (2004), 305–307 (*).
14. Cohen, M., Rasser, P.E., Peck, G., Carr, V.J., Ward, P.B., Thompson, P.M., Johnston, P., Baker, A., Schall, U., Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int. J. Neuropsychopharmacol. 15 (2012), 297–307 (*).
15. Cookey, J., Bernier, D., Tibbo, P., White matter changes in early phase schizophrenia and cannabis use: an update and systematic review of diffusion tensor imaging. Schizophr. Res. 156 (2014), 137–142.
16. Cunha, P.J., Rosa, P.G., Ayres, A.M., Duran, F.L.S., Santos, L.C., Scazufca, M., Menezes, P.R., Dos Santos, B., Murray, R.M., Crippa, J.A.S., Busatto, G.F., Schaufelberg, M.S., Cannabis use, cognition and brain structure in firs-episode psychosis. Schizophr. Res. 147 (2013), 209–215 (*).
17. Dekker, N., Schmitz, N., Peters, B.D., van Amelsvoort, T.A., Linszen, D.H., de Haan, L., Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res. 181 (2010), 51–56 (*).
18. Deshmukh, A., Rosenbloom, M.J., De Rosa, E., Sullivan, E.V., Pferfferbaum, A., Regional striatal volume abnormalities in schizophrenia: effects of comorbidity for alcoholims, recency of alcoholic drinking and antipsychotic medication type. Schizophr. Res. 79 (2005), 189–200 (*).
19. Di Lorenzo, R., Galliani, A., Guicciardi, A., Landi, G., Ferri, P., A retrospective analysis focusing on a group of patients with dual diagnosis treated by both mental health and substance use services. Neuropsychiatr. Dis. Treat. 10 (2014), 1479–1488.
20. Ebdrup, B.H., Glenthoj, B., Rasmussen, H., Aggernaes, B., Langkilde, A.R., Paulson, O.B., Lublin, H., Skimminge, A., Baaré, W., Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J. Psychiatry Neurosci. 35:2 (2010), 95–104 (*).
21. Epstein, K.A., Kumra, S., Executive attention impairment in adolescents with schizophrenia who have used cannabis. Schizophr. Res. 157:1–3 (2014), 48–54 (*).
22. Ferraro, L., Russo, M., O'Connor, J., Wiffen, B.D., Falcone, M.A., Sideli, L., Gardner-Sood, P., Stilo, S., Torotta, A., Dazzan, P., Mondelli, V., Taylor, H., Friedman, B., Sallis, H., La cascia, C., La Barbera, D., David, A.S., Reichenberg, A., Murray, R.M., Di Forti, M., Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr. Res. 150:1 (2013), 129–135.
23. Frajo-Apor, B., Pardeller, S., Kemmler, G., Welte, A., Hofer, A., Emotional intelligence deficits in schizophrenia: the impact of non-social cognition. Schiz. Res. 172 (2016), 131–136.
24. Gizewski, E.R., Muller, B.W., Scherbaum, N., Lieb, B., Forsting, M., Wiltfang, J., Leygraf, N., Schiffer, B., The impact of alcohol dependence on social brain function. Addict. Biol. 18 (2012), 109–120 (*).
25. Ho, B., Wassink, T.H., Ziebell, S., Andreasen, N.C., Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr. Res. 128:1–3 (2011), 66–75 (*).
26. James, A., Hough, M., Winmill, L., Burge, L., Nijhawan, S., Matthews, P.M., Zarei, M., Greater White and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophr. Res. 128:1–3 (2011), 91–97 (*).
27. Joyal, C.C., Halle, P., Lapierre, D., Hodgins, S., Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr. Res. 63:3 (2003), 297–299 (*).
28. Joyal, C.C., Pennanen, C., Tiihonen, E., Laakso, M.P., Tiihonen, J., Aronen, H., MRI volumetry of the vermis and the cerebellar hemispheres in men with schizophrenia. Psychiatry Res. 131 (2004), 115–124 (*).
29. Koenders, L., Machielsen, M.W.J., van der Meer, F.J., van Gasselt, A.C.M., Meijer, C.J., van den Brink, W., Koeter, M.W.J., Caan, M.W.A., Cousij, J., den Braber, A., vańt Ent, D., Rive, M.M., Schene, A.H., van de Giessen, E., Huyser, C., de Kwaasteniet, B.P., Veltman, D.J., de Haan, L., Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J. Psychiatry Neurosci. 40:3 (2015), 197–205 (*).
30. Kumra, S., Robinson, P., Tambyraja, R., Jensen, D., Schimunek, C., Houri, A., Reis, T., Lim, K., Parietal lobe volume deficits in adolescents with cannabis use disorders. J. Am. Acad. Child Adolesc. Psychiatry 51:2 (2012), 171–180 (*).
31. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P.A., Clarke, M., Devereaux, P.J., Kleijnen, J., Moher, D., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions. Ann. Intern. Med. 151 (2009), W65–W94.
32. Loberg, E., Nygard, M., Berle, J., Jonhsen, E., Kroken, R.A., Jogersen, H.A., Hugdahl, K., An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Front. Psychiatry 30 (2012), 1–11 (*).
33. Joyce, E., Hutton, S.M., Mutsatsa, S., Barnes, T.R.E., Cognitive heterogeneity in first-episode schizophrenia. Br. J. Psychiatry 187 (2005), 515–522.
34. Malchow, B., Hasan, A., Schneider-Axmann, T., Jatzko, A., Gruber, O., Schmitt, A., Falkai, P., Wobrock, T., Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 263 (2013), S155–S168 (*).
35. Malchow, B., Hasan, A., Fusar-Poli, P., Schmitt, A., Falkai, P., Wobrock, T., Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur. Arch. Psychiatry Clin. Neurosci. 263 (2013), 3–13.
36. Mancini-Marie, A., Potvin, S., Fahim, C., Beauregard, M., Mensour, B., Stip, E., Neural correlates of the affect regulation model in schizophrenia patients with substance use history: a functional magnetic resonance imaging study. J. Clin. Psychiatry 67:3 (2006), 342–350 (*).
37. Margolese, H.C., Malchy, L., Negrete, J.C., Tempier, R., Gill, K., Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr. Res. 67:2–3 (2004), 157–166.
38. Mathalon, D.H., Pfefferbaum, A., Lim, K.O., Rosenbloom, M.J., Sullivan, E.V., Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Arch. Gen. Psychiatry 60 (2003), 245–252 (*).
39. Onwuamaze, O.E., Nam, K.W., Epping, E.A., Wassink, T.H., Ziebell, S., Andreasen, N.C., Ho, B.C., MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol. Med. 43:3 (2013), 1–20 (*).
40. Padmanabhan, J.L., Tandon, N., Haller, C.S., Mathew, I.T., Eack, S.M., Clementz, B.A., Pearlson, G.D., Sweeney, J.A., Tamminga, C., Keshavan, M.S., Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar I disorders. Schizophr. Bull. 41:1 (2015), 154–162.
41. Peters, B.D., de Haan, L., Vlieger, E., Majoie, C.B., den Heeten, G.J., Linszen, D.H., Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity. Psychopharmacol. Bull. 2 (2009), 75–87 (*).
42. Potvin, S., Sepehry, A.A., Stip, E.A., A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol. Med. 36 (2006), 431–440.
43. Rais, M., Cahn, W.C., van Haren, N., Schnack, H., Caspers, E., Hulshoff Pol, H., Kahn, R., Excessive brain volume loss over time in cannabis-using first episode schizophrenia patients. Am. J. Psychiatry 165:4 (2008), 490–496 (*).
44. Rais, M., van Haren, N.E.M., Cahn, W., Shnack, H.G., Lepage, C., Collins, L., Evans, A.C., Hulshoff Pol, H.E., Kahn, R.S., Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur. Neuropsychopharmacol. 20 (2010), 855–865 (*).
45. Rapp, C., Bugra, H., Riecher-Rössler, A., Borgwardt, S., Effects of Cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post-mortem studies. Curr. Pharm. Des. 18 (2012), 5070–5080.
46. Scheller-Gilkey, G., Lewine, R.R.J., Caudle, J., Brown, F.W., Schizophrenia, substance use and brain morphology. Schizophr. Res. 35 (1999), 113–120 (*).
47. Schiffer, B., Muller, B.W., Scherbaum, N., Forsting, M., Wiltfang, J., Leygraf, N., Gizewski, E.R., Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain 133 (2010), 3093–3103 (*).
48. Schmidt, L.M., Jesse, M., Lykke, J., The impact of substance use disorders on the course of schizophrenia: a 15-year follow-up study Dual diagnosis over 15 years. Schizophr. Res. 130 (2011), 228–233.
49. Seidman, L.J., Pantelis, C., Keshavan, M.S., Faraone, S.V., Goldstein, J.M., Horton, N.J., Makris, N., Peter, F., Caviness, V.S., Tsuang, M.T., A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a MRI morphometric family study of the parahippocampal gyrus. Schizophr. Bull. 29:4 (2003), 803–830.
50. Smith, M.J., Cobia, D.J., Wang, L., Alpert, K.I., Cronenwett, W.J., Goldman, M.B., Mamah, D., Barch, D.M., Breiter, H., Csernansky, J.G., Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. Schizophr. Bull. 40:2 (2014), 287–299 (*).
51. Smith, M.J., Wang, L., Cronenwett, W., Goldman, M.B., Mamah, D., Barch, D.M., Csernansky, J., Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia. Schizophr. Res. 131:1 (2011), 174–183 (*).
52. Solowij, N., Walterfang, M., Lubman, D.I., Whittle, S., Lorenzetti, V., Styner, M., Velakoulis, D., Pantelis, C., Yucel, M., Alteration to hippocampal shape in cannabis users with and without schizophrenia. Schizophr. Res. 143 (2013), 179–184 (*).
53. Solowij, N., Yucel, M., Respondek, C., Whittle, S., Lindsay, E., Pantelis, C., Lubman, D.I., Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol. Med. 41 (2011), 2349–2359 (*).
54. Sullivan, E.V., Deshmukh, A., Desmond, J.E., Mathalon, D.H., Rosenbloom, M.J., Lim, K.O., Pfefferbaum, A., Contribution of alcohol abuse to cerebellar volume deficits in men with schizophrenia. Arch. Gen. Psychiatry 57 (2000), 894–902 (*).
55. Sullivan, E.V., Rosenbloom, M.J., Serventi, K.L., Deshmukh, A., Pferfferbaum, A., Effects of alcohol dependence comorbidity and antipsychotic medication on volumes of the thalamus and pons in schizophrenia. Am. J. Psychiatry 160:6 (2003), 1110–1116 (*).
56. Suokas, J.T., Perälä, J., Suominen, K., Saarni, S., Lönnqvist, J., Suvisaari, J.M., Epidemiology of suicide attempts among persons with psychotic disorder in the general population. Schizophr. Res. 124:1 (2010), 22–28.
57. Szeszko, P.R., Robinson, D.G., Sevy, S., Kumra, S., Rup, C.I., Bentensky, J.D., Lencz, T., Ashtari, M., Kane, J.M., Malhotra, A.K., Gunduz-Bruce, H., Napolitano, B., Bilder, R.M., Anterior cingulate grey-matter déficits and cannabis use in first-episode schizophrenia. Br. J. Psychiatry 190 (2007), 230–236 (*).
58. Thoma, P., Daum, I., Comorbid substance use disorder in schizophrenia: a selective overview of cognitive underpinnings. Psychiatry Clin. Neurosci. 67 (2013), 367–383.
59. Urrútia, G., Bonfill, X., PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses. Med. Clin. 135:11 (2010), 507–511.
60. Wobrock, T., Sittinger, H., Behrendt, B., D'Amelio, R., Falkai, P., Caspari, D., Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur. Arch. Psychiatry. Clin. Neurosci. 257 (2006), 203–210.
61. Wobrock, T., Sittinger, H., Behrendt, B., D'Amelio, R., Falkai, P., Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur. Arch. Psychiatry Clin. Neurosci. 259:1 (2009), 28–36 (*).